Objective: To explore the application value of oral propranolol at different dose and timing of administration in infantile hemangioma. Methods: A total of 96 infants with hemangioma admitted into Hubei Jingzhou Central Hospital from Jan. 2017 to Jun. 2018 were extracted to be divided into the group A and the group B via the random number table

with 48 cases in each group. Both groups were treated with “step-by-step” treatment

the final maintenance dose of group A was 1.0 mg/(kg·d)

and the final maintenance dose of group B was 2.0 mg/(kg·d). The overall efficacy

time to significant efficacy and clinical cure

and the duration of continuous treatment were compared between two groups at the end of drug withdrawal. Two groups were divided into >3 months group and ≤3 months group according to the starting age of treatment

and the differences of the above indicators were compared. Incidences of adverse drug reactions and recurrence were recorded. Results: At the end of drug withdrawal

there was no statistically significant difference in the clinical cure rate between the group A and the group B (P>0.05). Among the clinically cured children

the time to significant efficacy and clinical cure in the group B was shorter than that in the group A (P<0.05). The duration of continuous treatment in the group A was longer than that in the group B (P<0.05). At the end of drug withdrawal

the clinical cure rate of ≤3 months group was higher than that of >3 months group

the difference was not statistically significant (P>0.05). Among the clinically cured children

the time to significant efficacy and clinical cure in ≤3 months group was shorter than that in >3 months group (P<0.05). The duration of continuous treatment in ≤3 months group was shorter than that in >3 months group (P<0.05). There was no significant difference in the incidences of adverse drug reactions and recurrence between two groups. Conclusion: In the clinical treatment of infantile hemangioma

propranolol 1.0 mg/(kg·d) can achieve the same clinical outcome as 2.0 mg/(kg·d)

which is more secure and does not increase the risk of recurrence. However

propranolol 1.0 mg/(kg·d) needs a longer course of treatment. In addition

early treatment with propranolol (less than or equal to 3 months of age) is more beneficial to improve the clinical cure rate and reduce the risk of recurrence.